Abstract
Background and aim: The natural progression of liver fibrosis and its association with biomarker changes have not been fully established. This study aimed to investigate liver fibrosis progression in patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection using a novel machine learning tool called 'Subtype and Stage Inference (SuStaIn).'
Methods: This single-center retrospective study included 168 patients (29 HBV, 50 HCV, 89 controls). All patients underwent gadoxetic acid-enhanced MRI. Biomarkers included serum markers (FIB-4, APRI) and imaging markers (Q-LSC, CEI, RV/TV). SuStaIn was used to identify disease progression patterns from cross-sectional data.
Results: The sequence of biomarker conversion was determined to be APRI, FIB-4, CEI, Q-LSC, and finally RV/TV. This sequence was consistent across both HBV and HCV groups.
Conclusions: Abnormalities in serum biomarkers occur first, followed by functional decline in gadoxetic acid uptake, and finally morphological changes like right lobe atrophy.
Introduction
Liver fibrosis, the progressive scarring of liver tissue due to chronic injury from viruses like Hepatitis B (HBV) and C (HCV), is a major clinical concern. While liver biopsy remains the diagnostic gold standard, its invasiveness and cost limit its use for routine monitoring. Non-invasive alternatives, such as serum biomarkers and MRI-based imaging, have been developed, but the chronological order in which these markers change during disease progression has remained unclear. Understanding this sequence is critical for early intervention and patient stratification. This study utilizes machine learning to infer a long-term timeline from cross-sectional data.
Methods and Materials
The study utilized Subtype and Stage Inference (SuStaIn), an unsupervised machine learning algorithm originally developed for neurodegenerative diseases. SuStaIn reconstructs disease timelines from cross-sectional data by identifying the most likely sequence of biomarker "conversions" (moving from normal to abnormal states).
Patient Cohort
The retrospective analysis included 168 individuals selected from an initial pool of 300 patients suspected of having liver disease.
The final cohort consisted of 29 HBV patients, 50 HCV patients, and 89 controls (low-risk patients with normal ALT levels and no chronic liver disease).
Biomarkers and Imaging
Five biomarkers were analyzed:
- Serum: APRI (aspartate aminotransferase to platelet ratio index) and FIB-4 (fibrosis-4 index).
- Functional Imaging: Quantitative liver-spleen contrast ratio (Q-LSC) and contrast index of liver-muscle (CEI) derived from gadoxetic acid-enhanced MRI. These measure the liver's active uptake of contrast agents.
- Anatomical Imaging: Right liver lobe to total liver volume ratio (RV/TV), measuring physical atrophy.
Results
The SuStaIn algorithm identified a consistent "Serum → Function → Form" progression pipeline across the study population. While the algorithm initially looked for different "subtypes" of progression, it found that the vast majority of patients (all HBV and 47/50 HCV) fit into a single, consistent progression model.
The Sequence of Decline
The most probable order of biomarker conversion was determined to be:
- APRI (Serum)
- FIB-4 (Serum)
- CEI (Functional Imaging)
- Q-LSC (Functional Imaging)
- RV/TV (Morphological/Anatomical)
Key Findings
- Universality: The progression pattern was nearly identical for both HBV and HCV, suggesting a common biological pathway for viral-induced fibrosis regardless of the specific viral trigger.
- Early Warning: APRI was identified as the earliest marker to become abnormal, suggesting it may be the most sensitive tool for initial screening.
- Functional vs. Structural: Functional MRI markers (CEI/Q-LSC) showed abnormalities before structural changes (RV/TV) were detectable, confirming that functional decline precedes physical atrophy.
Discussion and Conclusion
This study demonstrates that machine learning can effectively reconstruct disease timelines from one-time patient snapshots. The findings suggest that biochemical changes in the blood are the "canaries in the coal mine," followed by a decrease in the liver's functional ability to process contrast agents, and finally, physical shrinkage of the right lobe.
While the study is limited by its single-center retrospective design and focus on early-to-moderate progression, it provides a clear chronology of liver fibrosis. This "timeline" offers a roadmap for clinicians to better interpret non-invasive tests and intervene earlier in the disease process. Future work should involve longitudinal data to validate the SuStaIn-predicted sequence and explore if these patterns hold for other conditions like metabolic-associated steatohepatitis (MASH).
Summary updated